$IART News

Integra LifeSciences Holdings Corporation 2026 Q2 - Results - Earnings Call Presentation

Wells Fargo Maintains Equal-Weight on Integra Lifesciences, Raises Price Target to $18

Integra LifeSciences Holdings Corporation (IART) Q2 2026 Earnings Call Transcript

Integra LifeSciences (NASDAQ:IART) Surges Over 30% on Q2 Earnings Beat

Integra Lifesciences Sees Q3 Adj EPS $0.53-$0.61 vs $0.56 Est; Sees Sales $410.000M-$425.000M vs $418.100M Est

Integra Lifesciences Affirms FY2026 Adj EPS Guidance of $2.40-$2.50 vs $2.45 Est; Lowers FY2026 Sales Guidance from $1.662B-$1.702B to $1.654B-$1.695B vs $1.676B Est

Integra Lifesciences Q2 Adj. EPS $0.56 Beats $0.48 Estimate, Sales $418.761M Beat $418.647M Estimate

UBS Initiates Coverage On Integra Lifesciences with Neutral Rating, Announces Price Target of $19

Truist Securities Maintains Hold on Integra Lifesciences, Raises Price Target to $19

BMO Capital Initiates Coverage On Integra Lifesciences with Market Perform Rating, Announces Price Target of $19

Citigroup Maintains Neutral on Integra Lifesciences, Raises Price Target to $19

Integra LifeSciences: New Beginning

Integra LifeSciences Holdings Corporation (IART) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Integra LifeSciences Holdings Corporation 2026 Q1 - Results - Earnings Call Presentation

Citigroup Maintains Sell on Integra Lifesciences, Raises Price Target to $11

Wells Fargo Maintains Equal-Weight on Integra Lifesciences, Raises Price Target to $15

Integra LifeSciences Holdings Corporation (IART) Q1 2026 Earnings Call Transcript

Integra Lifesciences Q1 2026 Earnings Call Transcript

Integra Lifesciences Sees Q2 Adj EPS $0.44-$0.52 vs $0.53 Est; Sees Sales $410.000M-$425.000M vs $425.403M Est

Integra Lifesciences Raises FY2026 Adj EPS Guidance from $2.30-$2.40 to $2.40-$2.50 vs $2.35 Est; Affirms FY2026 Sales Guidance of $1.662B-$1.702B vs $1.674B Est